We read with interest the report of Pratt et al 1 concerning the use of autotransplantation using Ph-negative blood progenitor cells mobilized with hydroxyurea and G-CSF in chronic myeloid leukemia (CML) patients. The main conclusion of this study is that such a method provided a less toxic procedure for obtaining progenitor cells to support an intensive conditioning regimen. Unfortunately, the number of patients transplanted was small and the observation period of post-transplantation too short to infer the possible clinical benefit of this procedure. We wish to add our experience using a similar approach in CML, initiated in March 1995 and reported recently, 2 autografting a large number of patients using this type of mobilization.
Autografting with peripheral blood stem cells mobilized with high doses of hydroxyurea and G-CSF was used in 15 patients with Ph-positive CML. The median age was 41 years (range 27-58), 10 were female and five male. At mobilization according to IBMTR criteria, 3 11 were in chronic phase but with a prolonged course, three in accelerated phase and one in complete remission after lymphoblastic crisis.
Mobilization was carried out using hydroxyurea (HU) at 1 g/m 2 /day and was stopped when less than 1 × 10 9 /l leukocytes in the peripheral blood was reached. The day after finalization of HU, G-CSF was administered s.c. at 10 g/kg body weight and was continued until the last day of harvesting. To define the first day of harvesting, combined criteria were considered: a neutrophil count higher than 1 × 10 9 /l, platelets higher than 20 × 10 9 /l and the appearance of CD34 + cells in the peripheral blood. 4 FISH studies were carried out using the m-bcr/abl translocation DNA probe (Oncor, Gaithersburg, USA).
All patients were successfully harvested using one mobilization procedure. The total dose of HU utilised, to obtain less than 1 × 10 9 /l leukocytes was extremely variable (16 -141 g) administered for 6-38 days (median 13). Recovery from neutropenia was achieved in a median of 14 days. Four patients required admission with fever. The number of apheresis ranged between one and five (median 2). The mean number of mononuclear cells obtained was 5.2 × 10 8 /kg (2.8-7.9) and the mean number of CD34 + cells was 6.7 × 10 6 /kg (0.3-28.5). Patients were autotransplanted using busulfancyclophosphamide conditioning in the first two and busulfan (16 mg/kg) in the rest, with less toxicity as was recently reported. 5 The median time to recovery of more than 0.5 × 10 9 /l neutrophils was 14 days (11-37) and of platelet engraftment (Ͼ20 × 10 9 /l) 16 days (0-91). Despite a high toxicity (mucositis grade у3 in eight cases and VOD in two cases). No patient died during the transplant procedure. All patients received alpha-interferon as maintenance treatment post-transplantation when the platelet count was higher than 50 × 10 9 /l and the leukocyte count higher than 3 × 10 9 /l in the peripheral blood. One patient was more than 1 year without alpha-interferon and was in clinical remission and the rest of the patients required prompt treatment. Regardless of the time to initiation of maintenance, all the patients relapsed (cytogenetically and/or clinically).
To date, with observation periods varying from 2 to 26 months, 11 patients are alive and four in cytogenetic remission according to FISH (bcr/abl translocation was considered negative with less than 10 positive metaphases of 200 total metaphases). This mobilization procedure makes it possible to harvest hematopoietic cells in CML with a low toxicity. This simpler approach could encourage the recruitment of more CML patients to autologous transplantation. Wider experience and more prolonged follow-up of the patients is required to answer the question of whether it could positively affect the clinical course of CML.
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